C3.ai Digital Transformation Institute Announces Research Awards for AI to Transform Cybersecurity and Secure Critical Infrastructure
24.3.2022 13:00:00 EET | Business Wire | Press release
C3.ai Digital Transformation Institute (C3.ai DTI) today announced the third round of C3.ai DTI funded advanced research awards, focused on using artificial intelligence (AI) to harden information security and secure critical infrastructure.
The Institute awarded a total of $6.5 million in cash awards to leading research scientists at University of California, Berkeley, University of Illinois at Urbana-Champaign, Carnegie Mellon, Princeton, University of Chicago, KTH Royal Institute of Technology, and MIT.
“Cybersecurity is an immediate existential issue,” said Thomas M. Siebel, chairman and CEO of C3 AI, a leading enterprise AI software provider. “We are equipping top scientists with the means to advance technology to help secure critical infrastructure.”
Twenty-four projects were awarded $100,000 to $700,000 each, for an initial period of one year:
AI Resilience: Techniques and methods to enable the development of AI algorithms that are resilient to adversarial attacks
- “High Performance Provably Robust AI Methods for Cybersecurity Tasks on Critical Infrastructure,” (Zico Kolter, Carnegie Mellon University)
- “Scalable, Secure Machine Learning in the Presence of Adversaries,” (John Kubiatowicz, University of California, Berkeley)
- “REFL: Resilient Distributed Cybersecurity Learning System,” (Bo Li, University of Illinois at Urbana-Champaign)
- “Fundamental Limits on the Robustness of Supervised Machine Learning Algorithms,” (Ben Zhao, University of Chicago)
Anomaly Detection: AI techniques, including supervised and unsupervised learning, to provide early detection of system and/or network anomalies that might be indicative of unauthorized access, denial of service, or data exfiltration
- “Continuously and Automatically Discovering and Remediating Internet-Facing Security Vulnerabilities,” (Nick Feamster, University of Chicago)
- “AI Techniques for Power Systems Under Cyberattacks,” (Javad Lavaei, University of California, Berkeley)
- “Physics-aware AI-based Approach for Cyber Intrusion Detection in Substation Automation Systems,” (Alberto Sangiovanni-Vincentelli, University of California, Berkeley)
Advanced Persistent Threats: AI techniques to detect the presence of advanced persistent threats
- “Deep-Learning Detection Algorithms for Advanced Persistent Attacks in Mixed-Autonomy Traffic: Design and Experimental Validation,” (Alex Bayen, University of California, Berkeley)
- “AI Support for Cybersecurity,” (David Wagner, University of California, Berkeley)
Securing Critical Cyber-Physical Infrastructure: AI techniques to secure critical infrastructure against cyber threats
- “Cyber Safety Cage for Networks,” (Cyrille Valentin Artho, KTH Royal Institute of Technology)
- “Security for Large-Scale Infrastructure using Probabilistic Programming,” (Nikita Borisov, University of Illinois at Urbana-Champaign)
- “A Compositional Neural Certificate Framework for Securing Critical Networked Infrastructure,” (Chuchu Fan, Massachusetts Institute of Technology)
- “Democratizing AI-Driven Security Workflows for Critical Energy Infrastructure,” (Vyas Sekar, Carnegie Mellon University)
- “Semantic Adversarial Analysis for Secure Critical Infrastructure,” (Sanjit Seshia, University of California, Berkeley)
Forensics: AI forensics and attribution techniques to identify sources of attacks
- “Causal Reasoning for Real-Time Attack Identification in Cyber-Physical Systems,” (György Dán, KTH Royal Institute of Technology)
- “Statistical Learning Theory and Graph Neural Networks for Identifying Attack Sources,” (H. Vincent Poor, Princeton University)
- “Robust and Scalable Forensics for Deep Neural Networks,” (Ben Zhao, University of Chicago)
Securing Emerging Financial Infrastructure: AI techniques to identify attacks on emerging decentralized financial and business infrastructure
- “An Intelligence Platform for Better Security in Decentralized Finance,” (Dawn Song, University of California, Berkeley)
- “Blockchain Forensics,” (Pramod Viswanath, University of Illinois at Urbana-Champaign)
Vulnerability Identification: AI techniques to identify previously unknown malware, ransomware, and zero-day vulnerabilities, enabling isolation and neutralization
- “GAN-Aided Automatic Test Case Generation,” (Giulia Fanti, Carnegie Mellon University)
- “Machine Learning for JavaScript Vulnerability Detection,” (Corina Pasareanu, Carnegie Mellon University)
Insider Threats: Change management techniques to prevent the weaponization of innocent and malicious insiders
- “Protecting Critical Infrastructures Against Evolving Insider Threats,” (Carl Gunter, University of Illinois at Urbana-Champaign)
- “Multi-Facet Rare Event Modeling of Adaptive Insider Threats,” (Jingrui He, University of Illinois at Urbana-Champaign)
- “AI-Supported Nudging for Cyber-Hygiene,” (Cedric Langbort, University of Illinois at Urbana-Champaign)
Award Criteria
C3.ai DTI selects research proposals that inspire cooperative research and advance machine learning and other AI subdisciplines. Projects are peer-reviewed on scientific merit, prior accomplishments of the principal investigator and co-principal investigators, the use of AI, machine learning, data analytics, and cloud computing in the research project, and the suitability for testing the methods at scale. Visit C3DTI.ai to learn more about the Institute’s programs, award opportunities, and selected research proposals.
About C3.ai Digital Transformation Institute
Established in March 2020 by C3 AI, Microsoft, and leading universities, the C3.ai Digital Transformation Institute is a research consortium dedicated to accelerating the benefits of artificial intelligence for business, government, and society. The Institute engages the world’s leading scientists to conduct research and train practitioners in the new Science of Digital Transformation — operating at the intersection of artificial intelligence, machine learning, cloud computing, internet of things, big data analytics, organizational behavior, public policy, and ethics.
The 10 C3.ai Digital Transformation Institute consortium member universities and laboratories are: University of California, Berkeley, University of Illinois at Urbana-Champaign, Carnegie Mellon University, KTH Royal Institute of Technology, Lawrence Berkeley National Laboratory, Massachusetts Institute of Technology, National Center for Supercomputing Applications at University of Illinois at Urbana-Champaign, Princeton University, Stanford University, and University of Chicago. Additional industry partners include AstraZeneca, Baker Hughes, and Shell.
To support the Institute, C3 AI is providing the Institute $57,250,000 in cash contributions over the initial five years of operation. In addition to cash awards, C3.ai DTI provides researchers with cloud computing, supercomputing, data, and software resources, including free, unlimited use of the C3 AI Application Platform, up to $2 million in Azure Cloud computing resources, and access to High Performance Computing (HPC) resources at the National Center for Supercomputing Applications (NCSA) at the University of Illinois at Urbana-Champaign and Lawrence Berkeley National Laboratory’s National Energy Research Scientific Computing Center (NERSC).
About C3.ai, Inc.
C3 AI is the Enterprise AI application software company. C3 AI delivers a family of fully integrated products including the C3 AI Application Platform, an end-to-end platform for developing, deploying, and operating enterprise AI applications and C3 AI Applications, a portfolio of industry-specific SaaS enterprise AI applications that enable the digital transformation of organizations globally. Learn more at: www.c3.ai.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220324005202/en/
Contact information
C3.ai DTI Contact:
Kap Stann
Communications Manager, C3.ai DTI @ Berkeley
510-295-9685
kstann@berkeley.edu
C3 AI Public Relations:
Edelman
Lisa Kennedy
415-914-8336
pr@c3.ai
C3 AI Investor Relations
ir@c3.ai
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
